Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Im Confused why would there be a proxy when they have enough cash for more than a year Also there is NO need for a RS at this time They can still file for an extension and they may believe that upcoming catalysts should bring the share price well over a dollar
I'm wondering if this prospectus is being used as leverage in a potential partnership negotiation.
In other words ' I can get the money without you' so you better come up with a better offer.
From reading the 10k it appears they are going to have to do a reverse split as early as this week
Could options expiration next week be influencing the action
Why hasn't anyone discussed Coleman selling all of those share in February ? An insider selling huge amount of shares is not exactly an endorsement.
Although a partnership deal would b great, kinda seems that if he has it,he needs to announce it now. He has a fiduciary responsibility to announce material events in a timely manner.
Amen !!!! Its Retts and PDD that could very well easily jump AVXLs market cap to $3-4B over the next 12 months.
When discussing valuations, it seems everyone is focused solely on AD. I challenge everyone to evaluate SRPT and their market cap who has a drug for the rare disease DMD. Look at their trials to include population size. My point is if the Rett and/or PDD short trials yield positive results, AVXL market cap will race beyond $2B ( which with say 50M shares out would be $40 )
2019 is go time
I read most of the posts here and it seems that 99% of them are all about AD. As much as I want a cure for all CNS diseases, as an investor , PDD and RS are the reasons I have invested here for the near term. If the 7 week RS data leads to a 3 month clinical trial with positive results, I believe a $1-2B market cap is ours. For those of you who follow the rare disease bios, a very good barometer is SRPT which I followed and invested in for years, PDD is a huge bonus if successful.
AD is icing on the cake and the elephant in the room but RS and PDD are the cats for the next 6-9 months.
Missling said it would be a catalyst.....one of my friends spoke to a company rep who said expect something good,,,,,,,so i guess we'll see
So I understand, you do not believe in AVXL's drug and prefer NTRP's
$1B market cap with 45M shares out actually equals $22 per share
Since the world wide total enrollment for the AD trial is 450 patients, what is the number for Australia ? And since they are ahead of the planned North America trial(s), would we see the results from there much sooner?
Great and right on target. One of my partners spoke with company and came away with this notion. They are trying to set the Rett. Trial up as pivotal with the filing of an NDA at the successful conclusion.
Amen brother. We're dead if we don't work with the BIG BOYS. As unfortunate as it is, it's the reality.
might want to correct her as its anavex not anovex
According to IR,,, Hampel is presenting and NOT Missling.
I believe this to be a positive.
this is a science conference. dr hampel presenting is significantly important. dr m showing data at a science conference does next to nothing, dr hampel showing and discussing it is a BIG DEAL. just wait, the science community admiration will lead to mkt cap appreciation.
game on
FYI Some traction and attention coming ........
https://finance.yahoo.com/news/fund-managers-shower-love-american-132101247.html
AVXL is fully reporting and has a market capitalization above $30M so I personally believe they won't be delisted from the Russell 3000.
It seems that most people keep forgetting this. If there is one thing that they have been consistent with,it is that both the RETT and PD trials are short 12 week precision medicine pivotal trials.
They appear to be the FIRST.
After listening to the conference and then looking at the responses on this board, I'm a little confused. The CC was exactly what was to be expected. Still committing to 3 trials starting during the next few months with no additional dilution.
Im pleased. Nothing negative. Just taking longer because of the precision medicine approach.
Going all in
I believe Missling MUST get a BP partner or the wall may prove insurmountable on several levels.
31M shares which includes preferred should be used for calculation purposes.
This looks like a one man army accomplishing a lot. However, no institutions would touch this with a ten foot pole. Need some sort of corporate structure with governance. What's the succession plan if he gets sick or worse ?
Maxim lowering their price target down to $5 after the last quarterly conference call was a killer.
How is Ltd related to intv
What does this have to do with intv. ?
How long will the INTV chart rely on bitcoin price.
Are they also heavy into blockchain
To me, this is huge. A significant step forward for the trial designs. Immensely increases the odds of success.
Are you actually saying something nice about AVXL's science ?
Are Aspires shares bought at 50 cents ? Also, how many shares do they hold ? What are Arudas terms ?
Tia
So it looks like Rett can start at any time now with a 12 week duration followed by analysis. As far as only 2 questions being asked....I think it was 2 questions allowed as I immediately went in queue and never got to ask my questions.
As somewhat of an aside, both of my parents as well as my mother-in-law died from alzheimers. so I naturally am very interested and hopeful that AVXL or ANY other company comes up with a viable drug to help.
as an investor, i see Rett and PD as the near term 1 yr money maker. If either shows promise. We will have at least a $1-$2 B market cap
Looks to be forming a new base at these levels
Mayo clinic.
Was thinking the same thing. There are quality of life variables that can't be definitively measured using the included protocol measures. They can be seen however. Even what's being measured is not entirely empirical.
How should I phrase this..... Instead of searching on a message board for answers to important questions, might it not make more sense to pick up a phone and ask a company representative?
More than Likely, just a few more trading days to acquire cheap shares.
Hint: interview discrepancy favorable to the nearest term
Didn't Gotlieb say 5 CNS trials to start this year.